Posted 5th July 2019 by Jane Williams
Fecal microbiota transplant (FMT) is probably the microbiome based therapy that has received the most media attention. It seems journalists love to talk about poo.
This has given momentum to research in the field. As the amount of trial data and fear of antibiotic resistance grows, FMT is now a much more common treatment for conditions like clostridioides difficile infection (CDI).
Posted 11th January 2018 by Jane Williams
Microbiome-based interventions, whether therapeutic or prophylactic, come in a broad spectrum of modalities, a consequence of the complexity of and possibilities afforded by the microbiome.
Posted 14th September 2017 by Jane Williams
“We need a shift from correlation to causation to support further progress,” says Weizmann Institute of Science’s Eran Elinav, echoing a widely espoused sentiment in the microbiome space. “We spent the first decade finding associations of microbiota with different clinical indications, but now we are discovering that only some of these are phenotypes that are caused by changed microbiota,” adds Elinav who is also scientific co-founder of Israel-based BiomX and DayTwo.
Posted 7th July 2017 by Jane Williams
The gut microbiota has become a favourite “organ” of the biomedical community, with the number of publications on different aspects of its architecture and function rising exponentially in the last few years. In part fuelled by advances in DNA sequencing technology, multiple studies have been conducted in patients with gastrointestinal (GI) related diseases (IBD, Coeliac, etc.) (1, 2).